三发性甲状旁腺功能亢进手术与药物治疗的系统综述
该系统综述检索了西那卡塞获批后发表的三发性甲状旁腺功能亢进治疗研究,共纳入47篇文献。手术治疗治愈率高于药物治疗,两种治疗方式的副作用和并发症均较轻且仅见于少数患者。
要点
- 手术治疗三发性甲状旁腺功能亢进的治愈率高于药物治疗。
核心结论
- 手术治疗三发性甲状旁腺功能亢进的治愈率高于药物治疗。
- 两种治疗方式的副作用和并发症均较轻且仅见于少数患者。
研究设计与样本
- 系统综述,检索西那卡塞获批后发表的医学文献数据库,共纳入47篇研究。
主要发现
- 关于移植物功能和生存的文献有限,但手术后肾移植物生存似乎与西那卡塞治疗相当。
关键数值与推荐
- 甲状旁腺全切除初始治愈率100%,复发率4%。
临床怎么用
- 对于三发性甲状旁腺功能亢进,手术治疗可获得更高的治愈率,应作为优先考虑的治疗选择。
局限性
- 关于移植物功能和生存的文献有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A significant proportion of patients with chronic kidney disease and secondary hyperparathyroidism (HPT) remain hyperparathyroid after kidney transplantation, a state known as tertiary HPT. Without treatment, tertiary HPT can lead to diminished kidney allograft and patient survival. Parathyroidectomy was commonly performed to treat tertiary HPT until the introduction of the calcimimetic drug, cinacalcet. It is not known whether surgery or medical treatment is superior for tertiary HPT. METHODS: A systematic review was performed and medical literature databases were searched for studies on the treatment of tertiary HPT that were published after the approval of cinacalcet. RESULTS: A total of 1669 articles were identified, of which 47 were included in the review. Following subtotal and total parathyroidectomy, initial cure rates were 98·7 and 100 per cent respectively, but in 7·6 and 4 per cent of patients tertiary HPT recurred. After treatment with cinacalcet, 80·8 per cent of the patients achieved normocalcaemia. Owing to side-effects, 6·4 per cent of patients discontinued cinacalcet treatment. The literature regarding graft function and survival is limited; however, renal graft survival after surgical treatment appears comparable to that obtained with cinacalcet therapy. CONCLUSION: Side-effects and complications of both treatment modalities were mild and occurred in a minority of patients. Surgical treatment for tertiary HPT has higher cure rates than medical therapy.
引用
- Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017. PMID: 28518414. doi:10.1002/bjs.10554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。